Palatin Technologies (LTS:0KF3) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KF3 Palatin Technologies Inc LTS:0KF3
29 GF Score
Price $11.08
GF Value $51.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Palatin Technologies Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

LTS:0KF3
29GF Score
Palatin Technologies Inc LTS:0KF3
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Palatin Technologies (LTS:0KF3) Overvalued in 2026?

Based on GuruFocus' analysis, Palatin Technologies stock appears to be undervalued. The current stock price of $11.08 is trading 78.3% below its estimated GF Value™ of $51.03. GuruFocus considers Palatin Technologies to be Possible Value Trap.

Key valuation signals for LTS:0KF3:

  • Interest Expense (Positive):
  • GF Value™: $51.03 vs. price of $11.08 (78.3% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the LTS:0KF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Palatin Technologies Business Description

Other Exchanges PTN:USA
Address 103 Carnegie Center Drive, Suite 300, Princeton, NJ, USA, 08852
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
29GF Score

Get the complete analysis for LTS:0KF3

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.08
Price
$51.03
GF Value